Can a GLP-1 Help With Sleep Apnea? What the Research Shows

If you use a CPAP machine every night, you know what obstructive sleep apnea does to your life — the interrupted sleep, the daytime exhaustion, the headaches, the strain on your heart. You may also know that your doctor has told you weight loss could help. What you may not know is that the FDA has now specifically approved a GLP-1 medication — Zepbound (tirzepatide) — for the treatment of moderate to severe obstructive sleep apnea in adults with obesity. This is the first medication ever approved for sleep apnea, and for seniors on Medicare, it opens an entirely new treatment pathway.

Why weight and sleep apnea are connected

Obstructive sleep apnea (OSA) occurs when the muscles and tissues in your throat relax during sleep, partially or completely blocking your airway. Excess weight — particularly fat deposits around the neck, throat, and upper airway — makes this blockage more likely and more severe. The more excess weight you carry, the more tissue presses on your airway when you lie down.

Research has consistently shown that approximately 60 to 70 percent of people with obstructive sleep apnea are overweight or obese. The relationship works in both directions: obesity worsens sleep apnea, and sleep apnea worsens obesity by disrupting hormones that regulate appetite and metabolism. Breaking this cycle with effective weight loss can significantly improve or even resolve sleep apnea in many patients.

The SURMOUNT-OSA trial: what it proved

In late 2024, the FDA approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity. This approval was based on the SURMOUNT-OSA trial, which studied tirzepatide specifically in patients with both obesity and OSA.

The trial results were striking. Participants taking tirzepatide experienced:

• A significant reduction in the apnea-hypopnea index (AHI) — the standard measure of sleep apnea severity, which counts the number of times per hour your breathing stops or becomes dangerously shallow during sleep.
• Average weight loss of approximately 18 to 20 percent of body weight.
• Improvements in blood oxygen levels during sleep.
• Reduced daytime sleepiness, as measured by the Epworth Sleepiness Scale.
• Some participants improved enough to move from severe to mild sleep apnea or to potentially discontinue CPAP therapy under medical supervision.

This was the first time any medication was approved by the FDA specifically for obstructive sleep apnea. Previously, the only treatment options were CPAP machines, oral appliances, positional therapy, and surgery.

What about Wegovy and sleep apnea?

While Zepbound is the only GLP-1 with an FDA-approved indication for sleep apnea, semaglutide (Wegovy) also produces significant weight loss that can improve OSA. Multiple studies have documented improvements in AHI scores among patients who lost weight on semaglutide, even though those studies were not specifically designed to measure sleep apnea outcomes.

If your doctor prescribes Wegovy rather than Zepbound — perhaps because of the cardiovascular benefits demonstrated in the SELECT trial — you may still see meaningful improvement in your sleep apnea as you lose weight. The sleep apnea improvement is primarily driven by the weight loss itself, regardless of which specific medication produces it.

How much weight loss does it take to improve sleep apnea?

Research from the Sleep Heart Health Study and other large trials suggests that even a 10 percent reduction in body weight can reduce AHI scores by approximately 26 percent. Greater weight loss produces greater improvement. A 20 percent weight loss — which is within the range of what GLP-1 medications can achieve — can reduce AHI by 50 percent or more in many patients.

For context, the AHI scale classifies sleep apnea severity as follows:

• Normal: fewer than 5 events per hour.
• Mild: 5 to 14 events per hour.
• Moderate: 15 to 29 events per hour.
• Severe: 30 or more events per hour.

A patient with severe sleep apnea (AHI of 40) who achieves a 50 percent reduction would move to an AHI of 20 — moderate range. While that still requires treatment, it represents a significant improvement in sleep quality, oxygen levels, and cardiovascular risk.

Will I be able to stop using my CPAP?

Some patients who achieve significant weight loss on GLP-1 medications do eventually discontinue CPAP therapy — but this decision must be made by your sleep specialist based on a follow-up sleep study, not by you based on how you feel. Feeling better is not the same as having a normal AHI.

Even if your symptoms improve dramatically, your sleep specialist will likely want to confirm with objective testing — either an in-lab sleep study or a home sleep apnea test — before recommending that you stop CPAP. Continuing CPAP during GLP-1 treatment is standard practice until clinical data confirms that your apnea has resolved or improved to a level where CPAP is no longer medically necessary.

The cardiovascular connection for seniors

Untreated obstructive sleep apnea significantly increases the risk of hypertension, heart attack, stroke, atrial fibrillation, and heart failure. For seniors who already face elevated cardiovascular risk, sleep apnea is not a minor inconvenience — it is a serious risk factor. Improving sleep apnea through weight loss on a GLP-1 medication addresses cardiovascular risk from two directions: the direct cardiovascular benefits of the medication (as demonstrated in the SELECT trial for semaglutide) and the indirect benefit of reduced sleep apnea burden on the heart.

How to bring this up with your doctor

If you have both obesity and sleep apnea, a GLP-1 medication may address both conditions with a single treatment. Here is how to start the conversation:

• Tell your primary care doctor or sleep specialist that you are interested in GLP-1 medication for both weight management and sleep apnea improvement.
• Ask whether Zepbound's FDA approval for sleep apnea changes your treatment options or coverage pathway.
• Request a baseline AHI measurement if you have not had a sleep study recently — this gives your doctor a number to compare against as you lose weight.
• Ask how often you should repeat the sleep study to track improvement — many specialists recommend retesting after 10 to 15 percent weight loss.
• Discuss whether you are a candidate for the Medicare Bridge program or whether the sleep apnea indication provides a separate coverage pathway.

Tracking your sleep quality, daytime energy levels, and symptoms on CairnSpace alongside your weight loss provides valuable data for your sleep specialist. Improvements in how rested you feel, how much daytime fatigue you experience, and how often you wake during the night can all be correlated with your weight loss progress.

Related Articles

• Wegovy vs Zepbound: Which GLP-1 Is Right for Seniors on Medicare?
• GLP-1 Medications and Heart Health: What the Cardiovascular Research Shows for Seniors
• Does Medicare Cover GLP-1 Weight Loss Medications in 2026?
• Medical Conditions That May Prevent You From Taking a GLP-1 — A Guide for Seniors

Sources

• FDA — approval of Zepbound (tirzepatide) for obstructive sleep apnea in adults with obesity (2024)
• SURMOUNT-OSA trial — tirzepatide and obstructive sleep apnea outcomes, Eli Lilly clinical program
• Peppard PE et al. — Longitudinal Association of Sleep-Related Breathing Disorder and Depression, Archives of Internal Medicine (2006)
• Sleep Heart Health Study — weight loss and AHI reduction data
• American Academy of Sleep Medicine — clinical practice guidelines for obstructive sleep apnea diagnosis and treatment